BJP College Seminars Series
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tran, P. V.
Right arrow Articles by Beasley, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tran, P. V.
Right arrow Articles by Beasley, C. M., Jr

The British Journal of Psychiatry 174: 15-22 (1999)
© 1999 The Royal College of Psychiatrists

Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy

PV Tran, GD Tollefson, TM Sanger, Y Lu, PH Berg and CM Beasley Jr
Psychopharmacology Division, Lilly Research Laboratories, Indianapolis, IN 46285, USA.

BACKGROUND: The effectiveness of antipsychotic monotherapy in schizoaffective disorder is limited, and further constrained by safety concerns. AIMS: We aimed to compare the efficacy, tolerability and safety profile of the new pharmaceutical, olanzapine, with haloperidol. METHOD: Data were assessed from 300 DSM-III-R schizoaffective subjects from a larger double-blind prospective international study. Subjects were randomly allocated to six weeks of olanzapine (5-20 mg) or haloperidol (5-20 mg) treatment; responders were followed for up to one year of double-blind, long-term maintenance therapy. RESULTS: Olanzapine-treated patients achieved a statistically significant greater improvement than haloperidol treated patients on overall measures of efficacy, including clinical response. Significantly fewer olanzapine patients left the study early, and fewer adverse events were observed among those receiving olanzapine. During maintenance, olanzapine-treated patients continued to experience additional improvement, with fewer EPS but more weight gain than those on haloperidol. CONCLUSIONS: Olanzapine demonstrated substantial advantages over the conventional antipsychotic haloperidol in the management of schizoaffective disorder.


This article has been cited by other articles:


Home page
 QJMHome page
W.S. Leslie, C.R. Hankey, and M.E.J. Lean
Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review
QJM, July 1, 2007; 100(7): 395 - 404.
[Abstract] [Full Text] [PDF]

Home page
 APPI Online CMEHome page
References
PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2.
[Full Text]

Home page
 Br. J. PsychiatryHome page
S. PARK, D. ROSS-DEGNAN, A. S. ADAMS, J. SABIN, P. KANAVOS, and S. B. SOUMERAI
Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: Population-based study
The British Journal of Psychiatry, August 1, 2005; 187(2): 137 - 142.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
K. A. Graham, D. O. Perkins, L. J. Edwards, R. C. Barrier Jr., J. A. Lieberman, and J. B. Harp
Effect of Olanzapine on Body Composition and Energy Expenditure in Adults With First-Episode Psychosis
Am J Psychiatry, January 1, 2005; 162(1): 118 - 123.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Bull.Home page
I. Maidment
Use of serotonin antagonists in the treatment of neuroleptic-induced akathisia
Psychiatr. Bull., September 1, 2000; 24(9): 348 - 351.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 1999 The Royal College of Psychiatrists.